menu
    • menu
    [{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Major Science & Tech Project China 11th Five-Year | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Telbivudine","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Major Science & Tech Project China 11th Five-Year | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Major Science & Tech Project China 11th Five-Year | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Major Science and Technology Special Project of China Twelfth-Five-Year Project | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Telbivudine","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Major Science and Technology Special Project of China Twelfth-Five-Year Project | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Major Science and Technology Special Project of China Twelfth-Five-Year Project | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Beijing YouAn Hospital","sponsor":"New Discovery","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Telbivudine","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Beijing YouAn Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing YouAn Hospital \/ New Discovery","highestDevelopmentStatusID":"11","companyTruncated":"Beijing YouAn Hospital \/ New Discovery"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Telbivudine","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telbivudine","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Lin Bingliang","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Telbivudine","moa":"DNA polymerase\/reverse transcriptase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Lin Bingliang","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Lin Bingliang"}]

    Find Clinical Drug Pipeline Developments & Deals for Telbivudine

    Menu

    Telbivudine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanfang Hospital, Southern Medical University

                            Country arrow
                            Tides Europe
                            Not Confirmed

                            Nanfang Hospital, Southern Medical University

                            Country arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Major Science and Technology Special Project of China Twelfth-Five-Year Project | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EFFORT Further Extension Study

                            Details : Telbivudine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2016

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Major Science and Technology Special Project of China Twelfth-Five-Year Project | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents Wit...

                            Details : Telbivudine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 07, 2014

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase IV

                            Sponsor : Lin Bingliang

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Tr...

                            Details : Telbivudine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B-associated with Liver Cirrhosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 26, 2013

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase IV

                            Sponsor : Lin Bingliang

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Beijing YouAn Hospital

                            Country arrow
                            Tides Europe
                            Not Confirmed

                            Beijing YouAn Hospital

                            Country arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : New Discovery

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

                            Details : Telbivudine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2012

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : New Discovery

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nanfang Hospital, Southern Medical University

                            Country arrow
                            Tides Europe
                            Not Confirmed

                            Nanfang Hospital, Southern Medical University

                            Country arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Major Science & Tech Project China 11th Five-Year | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EFFORT Extension Study

                            Details : Telbivudine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 08, 2012

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Major Science & Tech Project China 11th Five-Year | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

                            Details : Telbivudine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2011

                            Lead Product(s) : Telbivudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth